Abstract 420P
Background
KRAS mutations define a molecular subgroup of non-small cell lung cancer (NSCLC). KRAS G12C mutations can be targeted by small molecule inhibitors. Further investigation of cellular and molecular components of KRASm NSCLC is warranted to understand the disease mechanisms and guide precise treatment.
Methods
Tumor specimens of KRASm NSCLC were histologically evaluated, DNA and RNA were extracted. Comprehensive genomic and transcriptomic profiling were detected by Illumina TruSight Oncology 500 kit and TruSeq RNA Exome kit. Correlation analysis included demographic and clinical data as well.
Results
Among 162 cases of KRASm NSCLC, there were 141 males and 21 females, 140 adenocarcinoma and 8 squamous cell carcinoma, 2 sarcoid carcinoma, 1 large cell carcinoma and 1 NOS, 121 smokers and 41 non-smokers. Using next-generation sequencing (NGS), C>T transition signatures were found most often, followed by C>A, T>C, C>G, T>G, and T>A. KRAS mutations included 68 G12Cs, 33 G12Ds, 32 G12Vs, 9 G12As, 6 G13Ds, 6 Q61H/Ls and others. Major co-altered genes included TP53, LRP1B, FAT1, STK11, ARID1B, PTPRD, SPTA1, NOTCH3, NOTCH1, MGA, KEAP1, ZFHX3, etc. The genes co-alterations with KRAS were TP53 (59, 35.1%), followed by STK11 (27, 16.1%), STK11/TP53 (20, 11.9%), CDKN2A/TP53 (7, 4.2%), CDKN2A/STK11 (4, 3.4%) and CDKN2A/STK11/TP53 (3, 1.8%). Using MDACC's report, four groups were established: KL, KP, KC, and K-only. Correlation of genotypes with clinical outcome after adjuvant therapies will be analysed. Compared with adjacent tissues, KRASm cancer tissues had differentially expressed genes (DEGs) enriched in pathways of cytokine receptor interaction, primary immunodeficiency, intestinal immune network for IgA production, and etc. All KRAS tumors can be categorized into low and high inflamed groups by StromalScore, ImmuneScore and ESTIMATEScore methods.
Conclusions
Chinese KRAS mutant lung cancers are highly heterogeneous in terms of both KRAS mutations and co-altered genes and varied in inflammatory status in tumor microenvironment as well. Molecular and immune characteristics in KRASm NSCLC may influence the clinical outcome of adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract